Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology • Sarcoma • NCI-CCC Tumor Board Question • Ewing Sarcoma • AYA Tumor Board • ASCO 2022 • Northwestern University
In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?
J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024
Answer from: at Academic Institution
Yes, I would certainly consider offering high-dose ifosfamide to relapsed Ewing's sarcoma patients in light of the rEECur results [McCabe et al., J Clin Oncol 40, 2022 (suppl 17; abstr LBA2)]. The first line regimens I have traditionally offered to recurrent EWS patients have been topotecan/cyclopho...
Sign in or Register to read more
Answer from: at Community Practice
It is correct that the rEECur study concluded that high dose ifosfamide was superior in a non-significant comparison against cyclophosphamide/topotecan or irinotecan/temozolomide. However, in that study, the irinotecan/topotecan regimen used a 5-day schedule of irinotecan. A retrospective review of ...